MGMT and glioblastoma: Although GBM patients benefit from promoter hypermethylation of the O6-methylguanine-DNA methyltransferase (MGMT) that is the main determinant of resistance to TMZ, recent studies suggested that MGMT promoter methylation is of prognostic as well as predictive significance for the efficacy of TMZ.